Thank you, Mr. Chair.
Thank you to all the witnesses for being with us and thank you for your contributions.
My first question is for Dr. Volker Gerdts.
I recently had a discussion with Dynacare, a health care solution company, about once there is a vaccine ready to be distributed.
Dr. Robert Fowler, you can join in the answer, too.
What role do underlying health conditions and demographic factors play in the severity of COVID-19? How will this play into the effectiveness of a vaccine? Demographically, who will get the first access?